Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term neoadjuvant. Found 13 abstracts

Fareed MM, DeMora L, Esnaola NF, Denlinger CS, Karachristos A, Ross EE, Hoffman J, Meyer JE. Concurrent chemoradiation for resected gall bladder cancers and cholangiocarcinomas. Journal of gastrointestinal oncology. 2018 Aug;9(4):762-8.   PMCID: PMC6087856
Ghatalia P, Koenigsberg R, Pisarcik D, Handorf EA, Geynisman DM, Zibelman M. The Evolution of Clinical Trials in Renal Cell Carcinoma: A Status Report for 2013-2016 from the ClinicalTrials.gov Website. Kidney cancer. 2017 Nov 27;1(2):151-9.   PMCID: PMC6179107
Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, Retrospective International Study of Cancers of the Urothelial Tract I. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015 Aug;121(15):2586-93.
Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA. Ovarian Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Nov;10(11):1339-49.
Hamilton CA, Miller A, Miller C, Krivak TC, Farley JH, Chernofsky MR, Stany MP, Rose GS, Markman M, Ozols RF, Armstrong DK, Maxwell GL. The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: A gynecologic oncology group study. Gynecologic Oncology. 2011 Sep;122(3):521-6.   PMCID: *
Hamstra DA, Bae K, Pilepich MV, Hanks GE, Grignon DJ, McGowan DG, Roach M, Lawton C, Lee RJ, Sandler H. OLDER AGE PREDICTS DECREASED METASTASIS AND PROSTATE CANCER-SPECIFIC DEATH FOR MEN TREATED WITH RADIATION THERAPY: META-ANALYSIS OF RADIATION THERAPY ONCOLOGY GROUP TRIALS. International Journal of Radiation Oncology Biology Physics. 2011 Dec;81(5):1293-301.   PMCID: NIHMS285956
Sharma NK, Li TY, Chen DY, Pollack A, Horwitz EM, Buyyounouski MK. INTENSITY-MODULATED RADIOTHERAPY REDUCES GASTROINTESTINAL TOXICITY IN PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2011 Jun;80(2):437-44.   PMCID: PMC2909627
Roach M, Bae K, Lawton C, Donnelly BJ, Grignon D, Hanks GE, Porter A, Lepor H, Venketesan V, Sandler H. BASELINE SERUM TESTOSTERONE IN MEN TREATED WITH ANDROGEN DEPRIVATION THERAPY AND RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2010 Dec;78(5):1314-22.   PMCID: PMCID: PMC2920356 [Available on 2011/12/1]
Henry LR, Goldberg M, Scott W, Konski A, Meropol NJ, Freedman G, Weiner LM, Watts P, Beard M, McLaughlin S, Cheng JD. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: A phase II report. ANNALS OF SURGICAL ONCOLOGY. 2006 Feb;13(2):214-20.
Buyyounouski MK, Hanlon AL, Eisenberg DF, Horwitz EM, Feigenberg SJ, Uzzo RG, Pollack A. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. International Journal of Radiation Oncology Biology Physics. 2005 Dec;63(5):1455-62.
Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. International Journal of Radiation Oncology Biology Physics. 2005 Mar;61(3):695-701.
Yeung RS, Weese JL, Hoffman JP, Solin LJ, Paul AR, Engstrom PF, Litwin S, Kowalyshyn MJ, Eisenberg BL. Neoadjuvant Chemoradiation in Pancreatic and Duodenal Carcinoma - a Phase-Ii Study. Cancer. 1993 Oct;72(7):2124-33.
Yeung RS, Weese JL, Hoffman JP, Solin LJ, Paul AR, Engstrom PF, Litwin S, Kowalyshyn MJ, Eisenberg BL. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma: A Phase II study. Cancer. 1993 Jan;72(7):2124-33.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term neoadjuvant

neoadjuvant carcinoma phase-iii trial chemotherapy irradiation radiotherapy Prostate cancer adenocarcinoma adjuvant surgery external-beam radiotherapy chemoradiation prostate cancer radiation-therapy cancer conformal radiation-therapy randomized trial Radiation therapy radiation antigen duodenum locally advanced-carcinoma carboplatin pancreas survival resection mitomycin hypersensitivity bladder cancer Hormonal ablation Androgen prostate-specific antigen primary Androgen deprivation therapy Muscle Neoplasms plus cisplatin kidney cancer definitive radiotherapy therapy gemcitabine plus cisplatin cholangiocarcinoma (CCA) drug hypersensitivity analogs & derivatives androgen deprivation therapy Treatment Outcome radiology american society duodenum carcinoma Gallbladder cancer (GBC) doxorubicin induction resectability aggressive surgery replacement therapy Male Microscopic residual risk radical prostatectomy Urinary Bladder Neoplasms Intensity-modulated radiotherapy statistics & numerical data Neoadjuvant Therapy Clinical trials pathological stage pancreas carcinoma fallopian-tube 2006 i ds-v24-p2396 Retrospective Studies competing Female multimodality cancer therapy prognostic-factors group protocol 92-02 esophageal cancer dose-escalation trial Methotrexate paclitaxel population Age immunotherapy critique Serum testosterone recurrent epithelial ovarian muscle invasion androgen deprivation Antineoplastic Combined Chemotherapy Protocols preoperative chemoradiation androgen suppression follow-up regional pancreatectomy intraperitoneal cisplatin hypogonadal men advanced-stage ovarian ampulla Vinblastine fluorouracil Surgery Oncology Gastrointestinal toxicity neoadjuvant chemoradiotherapy competing risk Adult pegylated liposomal doxorubicin Retrospective failure suppression vinblastine treatment failure Middle Aged high risk deprivation therapy toxicity 80 and over Aged Cisplatin hypersensitivity reactions Transitional Cell Carcinoma Prognostic factors Doxorubicin Neoplasm Invasiveness methotrexate Epithelial ovarian cancer management secondary Aged surgical cytoreduction Metastasis drug therapy cisplatin dose escalation pathology trial debulking surgery portal-vein Deoxycytidine Cytoreduction level therapeutic use mortality prediction administration & dosage Multicenter Studies as Topic consensus definition
Last updated on Friday, January 03, 2020